Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neovacs SA ( (FR:ALNEV) ) just unveiled an announcement.
Néovacs has announced a fundraising of €0.25 million through the issuance of OCEANE-BSA, aimed at financing its Kinoïde® research program on allergies and enhancing investment in promising biotech and medtech projects. This operation, while providing necessary funds, also poses risks of significant share dilution and potential downward pressure on share prices, which could adversely affect current shareholders and the company’s market value.
More about Neovacs SA
Néovacs is a French biotechnology company engaged in both research and development and investment activities. It focuses on developing vaccine candidates using its kinoïde® technology platform, targeting conditions such as lupus and allergies through active immunotherapy.
YTD Price Performance: -97.77%
Average Trading Volume: 11,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €15.18K
See more insights into ALNEV stock on TipRanks’ Stock Analysis page.